Pfizer Supports Relief Efforts in Philippines
After Typhoon Haiyan devastated the central Philippines on Nov. 8, Pfizer and its colleagues contributed a combined $900,000 in cash and medicines to help people in the affected region.
To date, colleagues in the Philippines have pledged $23,000 in individual contributions to relief efforts. These donations will be matched one-to-one through the Pfizer Philippines Foundation.
In addition, the Pfizer Foundation has made cash grants of $250,000 each to the U.S. Fund for UNICEF (www.unicefusa.org) and World Vision (www.worldvision.org). Pfizer Emerging Markets Asia and Pfizer Philippines have also donated $150,000 to several organizations providing assistance locally. Donations are also expected from the local affiliates in Emerging Markets Asia and Consumer Health U.S.
“Given the rising cases of common and expected diseases after the typhoon, Pfizer also responded to the call for immediate medical assistance through medicine donation,” said Cristobal Dumo, Medical Director, Pfizer Philippines. “These Pfizer medicines amounting to $175,000 were provided to various organizations, including the Department of Health.”
Pfizer Philippines has donated cash or medicines to the following organizations:
· Philippine Red Cross
· UN World Food Programme
· Caritas Manila / Catholic Relief Services
· World Vision
· Philippine Business for Social Progress
· Sagip Kapamilya Foundation
· Alagang Kapatid Foundation
· GMA Kapuso Foundation
· PHAPCares Foundation
· Department of Health
· Philippine Medical Association
Aside from raising funds, Pfizer colleagues in the Philippines have also dedicated their time and effort to help several organizations in repacking relief goods for the typhoon victims.
“We are thankful for this opportunity to meaningfully work together for a cause greater than all of us,” said Patricia Pascual, Public Affairs, Communications and Market Access Director, Pfizer Philippines. “We are extremely grateful for the outpouring of support not only from local colleagues, but also from our colleagues.”